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Abstract
Background: The hematopoietic system is especially sensitive to total body irradiation (TBI), and myelosuppression
is one of the major effects of TBI. Astaxanthin (ATX) is a powerful natural anti-oxidant with low toxicity. In this study,
the effect of ATX on hematopoietic system injury after TBI was investigated.
Methods: Flow cytometry was used to detect the proportion of hematopoietic progenitor cells (HPCs) and
hematopoietic stem cells (HSCs), the level of intracellular reactive oxygen species (ROS), expression of cytochrome
C, cell apoptosis, and NRF2-related proteins. Immunofluorescence staining was used to detect Nrf2 translocation.
Western blot analysis was used to evaluate the expression of apoptotic-related proteins. Enzymatic activities assay
kits were used to analyze SOD2, CAT, and GPX1 activities.
Results: Compared with the TBI group, ATX can improve radiation-induced skewed differentiation of peripheral
blood cells and accelerate hematopoietic self-renewal and regeneration. The radio-protective effect of ATX is
probably attributable to the scavenging of ROS and the reduction of cell apoptosis. These changes were associated
with increased activation of Nrf2 and downstream anti-oxidative proteins, and regulation of apoptotic-related
proteins.
Conclusions: This study suggests that ATX could be used as a potent therapeutic agent to protect the
hematopoietic system against TBI-induced bone marrow suppression.
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Background
Accidental exposure to moderate or high doses of radi-
ation poses a significant threat to human health, especially
the hematopoietic system [1]. The hematopoietic system
is the most vulnerable system to the damaging effects of
total body irradiation (TBI), and doses greater than 1 Gy
induce bone marrow (BM) cell injury [2]. BM suppression
is also the main symptom of hematopoietic systemic in-
jury seen in the clinic when patients receive traditional
cancer therapy, such as radiotherapy, and this can cause
high mortality and morbidity which worsens the outcome
of cancer treatment [3, 4]. TBI-induced myelosuppression,
which presents mainly as pancytopenia, is due to apop-
tosis of the rapidly proliferating hematopoietic progenitor
cells (HPCs) and the relatively quiescent hematopoietic
stem cells (HSCs) [5]. Thus, efforts to reduce apoptosis
of HSCs not only help to attenuate TBI-induced HSC
depletion, but also relieve TBI-induced BM injury in
the hematopoietic system.
Under steady-state conditions HSCs are quiescent and
serve as a reserve to protect the hematopoietic system
from exhaustion against various stress conditions [6]. How-
ever, exposure to ionizing radiation (IR) can generate large
amounts of reactive oxygen species (ROS) in the cytosol of
mammalian cells, which results in severe oxidative stress.
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Although ROS are required for the physiological function
of cells, overproduction of these molecules damages cellu-
lar components, such as proteins, lipids, and DNA, par-
ticularly through DNA double-strand breaks (DSBs), which
finally results in hematopoietic cell injury [7, 8]. Nuclear
factor erythroid 2-related factor 2 (Nrf2) is a transcription
factor and a cellular sensor of oxidative stress [9]. In
response to oxidative stress, Nrf2 dissociates from its
cytoplasmic repressor kelch-like ECH-associated protein 1
(Keap1) and translocates into the nucleus, where it regu-
lates the transcription of a wide variety of anti-oxidant
genes, such as heme oxygenase-1(HO-1), NAD(P)H quin-
one oxidoreductases 1 (NQO1), and superoxide dismutase
(SOD) [10, 11]. Moreover, Nrf2 is found to promote the
survival of irradiated cells, including BM cells, through
ROS scavenging [12]. These findings indicate that it is im-
portant to explore potent anti-oxidants to prevent ROS
damage and protect HSCs from apoptosis caused by IR.
Astaxanthin (ATX), a natural anti-oxidant, is pre-
dominantly found in marine organisms and is the only
known carotenoid that can be transported into the
brain by transcytosis through the blood–brain barrier
[13]. It exhibits powerful anti-oxidant activity compared
to that of other carotenoids, such as canthaxanthin, lu-
tein, lycopene, vitamin E, α-carotene, and β-carotene
[14]. ATX can effectively scavenge intracellular free
radicals and destroy peroxide chain reactions, thereby
protecting cell and biological membranes from oxida-
tive damage [15]. Previous studies have shown that
ATX, owing to its biological source and superior anti-
oxidant properties, exhibits numerous health benefits,
including anti-tumor effects, anti-inflammatory actions,
anti-diabetic effects, hepatoprotective effects, and immu-
nomodulatory activity [16, 17]. Zhao and colleagues dem-
onstrated that 30 days of ATX administration (1 mg/kg, 2
mg/kg, and 4 mg/kg) before irradiation protected against
oxidative impairment and DNA damage in irradiated mice
liver cells [18]. When referred to the hematopoietic sys-
tem, ATX increased the counts of peripheral granulocytes
and BM nucleated cells after mice received 8 Gy 60Co γ-
rays, which illustrated preliminary that ATX may alleviate
TBI-induced hematopoietic system injury. However, the
anti-oxidant effect of ATX on TBI-induced HSC and HPC
injury, and the underlying mechanisms have not been
studied. Moreover, several studies have shown that ATX
can attenuate apoptosis in many systemic diseases and
cells [15, 19]. These studies suggest that application of
ATX may alleviate hematopoietic cell apoptosis after TBI.
In this study, we explore the anti-oxidative and anti-
apoptotic properties of ATX in TBI-induced hematopoietic
system injury and the underlying molecular mechanisms.
The results show that ATX improved TBI-induced skewed
differentiation of peripheral blood cells and ameliorated
BM suppression by accelerating hematopoietic self-renewal
and regeneration. These findings were associated with the
scavenging of ROS according to Nrf2-mediated increased
activation of anti-oxidant proteins. Further study showed
that the reduction of apoptosis in c-kit positive cells by
regulating apoptotic-related proteins is also attributable to
the radioprotective effects of ATX.
Methods
Reagents
Anti-mouse CD117 (c-kit)-APC (clone 2B8), anti-mouse
Ly-6 A/EA (Sca-1)-PE/Cy7 (clone D7), biotin-conjugated
anti-mouse CD4 (clone GK1.5), anti-mouse CD8 (clone
53–6.7), anti-mouse CD45R/B220 (cloneRA3-6B2), anti-
mouse Ly6G/Gr-1 (clone RB6-8C5), anti-mouse CD11b
(clone M1/70), anti-mouse Ter-119 (clone Ter-119), and
APC-Cy7-conjugated streptavidin were obtained from
eBioscience (San Diego, CA, USA). Anti-mouse CD45.1-
FITC (clone A20, Ly5.1), anti-mouse CD45.2-PE (clone104,
Ly5.2), anti-mouse Ly6G/Gr-1-PE/Cy7 (cloneRB6-8C5),
anti-mouse CD45R/B220-PerCP (cloneRA3-6B2), anti-
mouse CD11b-PE/Cy7 (cloneM1/70), anti-mouse CD3-
APC (clone145-2C11), and streptavidin-PerCP (405213)
were obtained from Biolegend (San Diego, CA, USA).
Anti-mouse γH2AX and anti-mouse cleaved CASPASE 3
antibodies were obtained from Cell Signaling Technology
(Danvers, MA, USA). Anti-mouse HO-1, anti-mouse
NQO1, anti-mouse cytochrome C, anti-mouse β-ACTIN,
anti-mouse NRF2, anti-mouse BAX, anti-mouse BAK, and
anti-mouse BCL-XL antibodies were obtained from Abcam
(Cambridge, UK). FITC-conjugated goat anti-rabbit/mouse
antibodies were obtained from ZSGB-BIO (Beijing, China).
Cytofix/Cytoperm buffer and Perm/Wash buffer were ob-
tained from BD Pharmingen (San Diego, CA, USA). ATX
was obtained from Aladdin Co. (Shanghai, China).
Mice
Male C57BL/6 (CD45.2) mice were purchased from the
Beijing HFK Bioscience Co. Ltd. (Beijing, China). Male
C57BL/6 (CD45.1) mice were purchased from the Insti-
tute of Hematology and Blood Disease Hospital
(PUMC, Tianjin, China). Nrf2−/− mice were generously
provided by Dr. Thomas W. Kensler of the University of
Pittsburgh, USA. All mice were approximately 6–8 weeks
old (20–22 g) and housed under specific pathogen-free
conditions at the Experimental Animal Centre of the
Institute of Radiation Medicine of PUMC. All animal
studies were approved by the Animal Care and Ethics
Committee of the Institute of Radiation Medicine of
PUMC (SYXK-2014-0002).
TBI and ATX administration
Two batches of CD45.2 mice were respectively divided into
(1) five groups: control group, TBI group, TBI + 25 mg/kg
ATX group, TBI + 50 mg/kg ATX group, and TBI + 100
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mg/kg ATX group; and (2) four groups: control group,
ATX group, TBI group, TBI +ATX group (the ATX con-
centration was 50 mg/kg/day). Nrf2−/− mice were divided
into three groups: control, TBI alone group, and TBI +
ATX group. Each group had five mice. All mice that re-
ceived ATX were administrated the compound by gavage 3
days before irradiation and 7 days after irradiation. Mice in
all the TBI groups received 4 Gy γ-ray at a dose rate of 0.99
Gy/min. Control mice were sham-irradiated.
Weight and organ index
The mean body weights of the groups were plotted to
determine the weight gain or loss in the control and test
groups. Then the mice were sacrificed and the organs
were excised and weighed. Organ weights were recorded,
and indices (in g/g) were calculated by the ratio of the
wet weights of the individual organs to the whole body
weights.
Peripheral blood cell and bone marrow cell counts
Blood was obtained from the mice via the orbital sinus
and was collected in micropipettes coated with the eth-
ylenediaminetetraacetic acid (EDTA.K3). The cell counts
included white blood cells (WBCs), percentage of lym-
phocytes (LY%), and percentage of neutrophil granulo-
cytes (NE%). Bone marrow cells were flushed from both
the tibias and femurs with sterile phosphate-buffered sa-
line (PBS), and the cell numbers were counted using a
Celltac E hemocytometer (Nihon Kohden, Japan).
Flow cytometry analysis
For B cell, T cell, and myeloid cell analysis in peripheral
blood, 50 μl peripheral blood was first incubated with
B220, CD3, CD11b, and Gr1 at room temperature, and
then the red blood cells were removed with BD FACS™
Lysing Solution. For HPC and HSC analysis, bone mar-
row cells were isolated as described above. They were
then filtered and counted prior to staining with anti-
bodies. Bone marrow cells (5 × 106) were incubated with
biotin-labeled antibodies specific for murine Ter119,
B220, Gr1, CD11b, CD4, and CD8, and were then
stained with streptavidin, c-kit, and sca1. For HO-1,
NQO1, γH2AX, and cytosol cytochrome C (cyt C) ana-
lysis, bone marrow cells (5 × 106) were stained with c-kit
antibody, fixed, and permeabilized using BD Cytofix/
Cytoperm buffer according to the manufacturer’s proto-
col, and finally stained with respective antibodies and
FITC-conjugated secondary antibodies. Data acquisition
was performed using a BD Accuri C6 and analyzed using
BD Accuri C6 software.
Competitive repopulation assay
Bone marrow cells (1 × 106) from C57BL/6 (CD45.2)
mice after the various treatments and 1 × 106 bone
marrow cells from C57BL/6 (CD45.1/45.2) mice were
mixed and transplanted into lethally irradiated C57BL/6
mice (CD45.1). The percentage of donor-derived (CD45.2)
cells in the recipients’ peripheral blood was examined 2
months after transplantation.
Fig. 1 Astaxanthin (ATX) rescues the body weight loss and the organ
index changes caused by total body irradiation (TBI) in mice. Mice
were randomly divided into five groups and were administered either
DMSO or different concentrations of ATX by gavage for 3 days before
exposure to 4 Gy TBI and then continuously for 7 days after irradiation.
Control mice were sham-irradiated. a Bar graph showing the average
body weight of each group. b Bar graph showing the thymus
index. c Bar graph showing the lung index. The data are presented
as the mean ± SEM (N = 5). aP < 0.05 vs control; bP < 0.05 vs TBI
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Colony of granulocyte macrophage cells (CFU-GM) assay
Bone marrow cells (1 × 104) from the control groups and
1 × 105 bone marrow cells from the TBI groups were
cultured in M3534 methylcellulose medium (Stem Cell
Technologies) for 5 days. The colonies of CFU-GM with
more than 30 cells were counted according to the instruc-
tions. The results are expressed as the numbers of CFU-
GM per 105 bone marrow cells.
Analysis of intracellular ROS levels
Bone marrow cells (5 × 106) from wild mice or Nrf2−/−
mice were first stained with c-kit antibody, and were
then incubated with 2′, 7′-dichlorodihydrofluorescein
diacetate (DCFDA; Beyotime Biotechnology, Nanjing,
China; 10μM), MitoSOX (Life Technologies, Grand Is-
land, NY, USA; 10μM); and dihydroethidium (DHE;
Beyotime Biotechnology; 5μM) for 20 min, 30 min, and
10 min, respectively, at 37 °C in a water bath according
to the manufacturer’s protocol. The levels of intracellular
ROS in c-kit-positive cells were analyzed by measuring
the mean fluorescence intensity (MFI) of DCFDA, DHE,
and oxidized MitoSOX using a flow cytometer.
Analysis of SOD2, CAT, and GPX1 activity
To isolate c-kit-positive cells, bone marrow cells were
stained with CD117 microbeads (Miltenyi Biotec,
Teterow, Germany) for 20 min at 2–8 °C, and the c-kit-
positive cells were collected according to the manufac-
turer’s protocol. SOD2, CAT, and GPX1 enzymatic
activities in c-kit-positive cells were analyzed using
SOD, CAT, and GPX1 assay kits (Beyotime Institute of
Biotechnology, Jiangsu, China), respectively, following
the manufacturer’s instructions.
Immunofluorescence staining of NRF2
c-kit-positive cells were sorted as described above, and
fixed in 4% paraformaldehyde for 10 min at room
temperature. Cells were permeabilized in 0.2% Triton-X-
100/PBS and blocked with 5% bovine serum albumin
Fig. 2 Astaxanthin (ATX) attenuates total body irradiation (TBI)-induced multilineage differentiation disorders and maintains hematopoietic
homeostasis. Mice were sham-irradiated as a control or irradiated with 4 Gy TBI after receiving DMSO or various concentrations of ATX in a manner
similar to that illustrated in Fig. 1. a Bar graph showing the numbers of white blood cells (WBC). b Bar graph showing the percentage of neutrophilic
granulocytes (NE%) and (c) lymphocytes (LY%). The percentage of T cells (d), B cells (e), and myeloid cells (f) in peripheral blood detected by flow
cytometry. The data are presented as the mean ± SEM (N = 5). aP < 0.05 vs control; bP < 0.05 vs TBI
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(BSA) for 1 h at room temperature, and then incubated
with anti-NRF2 antibody (1:300; overnight at 4 °C). Cells
were washed three times with PBS for 5 min, and incu-
bated with FITC-conjugated goat anti-rabbit IgG (1:300)
antibody in the dark for 1 h at room temperature. Finally,
a fluorescent sealing liquid solution (ZSGB-BIO, Beijing,
China) containing 4′,6-diamidino-2-phenylindole (DAPI)
was added to stain the nuclei. Fluorescence images were
visualized with a fluorescence microscope.
Apoptosis assay
Bone marrow cells (5 × 106) were first incubated with a
c-kit antibody, and cell apoptosis was then evaluated
using an Annexin V-FITC Apoptosis Detection Kit (BD
Biosciences, San Jose, CA, USA) followed by flow cytome-
try analysis according to the manufacturer’s protocol.
Finally, samples were evaluated by BD Accuri C6 and ana-
lyzed using BD Accuri C6 software.
Analysis of cytochrome C release from mitochondria in c-
kit-positive cells
c-kit-positive cells were sorted as described above. The
cytochrome C release from mitochondria in the c-kit-
positive cells was determined by analysis of the MFI by
flow cytometry according to the method described pre-
viously [20].
Western blotting analysis
c-kit-positive cells were collected as described above and
then lysed using RIPA reagent (Boster Biological, Wuhan,
China) supplemented with a protease inhibitor cocktail
(Sigma, St. Louis, MO, USA) and phenylmethylsulfonyl
fluoride (PMSF; Sigma). Proteins were separated by 12%
SDS-polyacrylamide gel electrophoresis, transferred to
nitrocellulose membranes (Sigma), and detected using spe-
cific antibodies as follows: β-ACTIN antibody (1:1000),
NRF2 antibody (1:1000), BAX antibody (1:1000), BAK anti-
body (1:1000), BCL-XL antibody (1:1000), and cleaved
CASPASE 3 antibody (1:1000). Blots were developed using
Molecular Imager Chemi Doc™ XRS+ with Image Lab™
Software (Bio-Rad, Richmond, CA, USA).
Statistical analysis
Statistical analysis was carried out using GraphPad
Prism 5 software with a t test and Welch’s correction.
Differences were considered significant at P < 0.05.
Fig. 3 Astaxanthin (ATX) treatment attenuates total body irradiation (TBI)-induced bone marrow cell reduction in vivo. Mice were randomly
divided into four groups and were administered DMSO or 50 mg/kg ATX by gavage for 3 days before exposure to 4 Gy TBI and then
continuously for 7 days after irradiation. Control/ATX mice were sham-irradiated. All mice were sacrificed at 12 days after exposure to TBI. The
numbers and frequencies of hematopoietic progenitor cells (HPCs) and LSK cells in bone marrow were then analyzed by flow cytometry. a Bar
graph showing the numbers of bone marrow cells per femur. b The numbers of HPCs (Lineage−Sca1−c-kit+ bone marrow cells) per femur. c The
numbers of LSKs (Lineage−Sca1+c-kit+ bone marrow cells) per femur. d Representative FACS plots show the percentages of HPC and LSK. The
data are presented as the mean ± SEM (N = 5). aP < 0.05 vs control; bP < 0.05 vs TBI
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Results
ATX rescues the loss of body weight and the changes in
organ index caused by TBI in mice
Compared to the control group, the body weight of the
TBI group had decreased significantly when mice were
sacrificed 12 days after 4 Gy irradiation. However, the
body weight of mice that received 25-100 mg/kg ATX
was significantly increased compared to that of the TBI
groups (Fig. 1a). In addition, compared with TBI group,
the index of thymus of the 50 mg/kg group was signifi-
cantly rescued, and the indices of lung in TBI + ATX
groups showed a significant improvement (Fig. 1b and
c). Our results suggested that 50 mg/kg ATX has
effective radioprotective effects on TBI-induced injury in
mice.
ATX can improve radiation-induced skewed differenti-
ation of peripheral blood cells
HSCs not only have the capacity for self-renewal but can
also differentiate into different blood cell lineages which
must be balanced to prevent lineage skewing [1]. To assess
the possible role of ATX in protecting the hematopoietic
system against radiation exposure, we examined the abun-
dance of different types of hematopoietic cells in peripheral
blood samples collected from the five groups described
above using a hemocytometer and flow cytometry. As
shown in Fig. 2, TBI-treated mice exhibited a substantial
reduction in WBCs and percentage of lymphocyte cells
(including T cells and B cells), while the percentage of neu-
trophils (NE%) and myeloid cells increased. Treatment
with 50 mg/kg ATX notably rescued impaired differenti-
ation of peripheral blood cells in the mice exposed to 4 Gy
radiation, which demonstrated that ATX can effectively
restore multilineage differentiation disorders and maintain
hematopoietic homeostasis.
ATX treatment attenuates TBI-induced bone marrow cell
reduction in vivo
To determine whether ATX treatment could promote
recovery of HSCs in vivo, we irradiated C57BL/6 mice
with 4 Gy and then treated them with 50 mg/kg ATX or
DMSO via oral gavage from day −3 to day +7. At day
Fig. 4 Astaxanthin (ATX) reduces total body irradiation (TBI)-induced suppression of BM cell clonogenic function and induces HSC reconstitution
in vivo. a Schematic diagram shows the recipients were transplanted with BM cells from the various treated groups. b Bar graph showing the
number of CFU-GM per 105 BM cells. c The scatter plot shows the percentage of donor-derived cells in peripheral blood cells 2 months after
transplantation. d Representative results of donor cell engraftment. The data are presented as the mean ± SEM (N = 6 in b and N = 10 in c). aP < 0.05 vs
control; bP < 0.05 vs TBI
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+12 following TBI, ATX-treated mice had increased
numbers of BM cells, LSK cells (Lin−Sca-l+c-kit+), and
HPCs (Lin−Sca-l−c-kit+), as well as increased percentages
of LSK cells and HPCs compared to vehicle-treated mice
(Fig. 3). These results suggested that ATX significantly
increased the recovery of BM HPCs/LSK cells after TBI.
Systemic administration of ATX improves HSC
regeneration in vivo
To determine if treatment with ATX could rescue the
reconstituted function of the HSC pool in irradiated mice,
we performed CFU-GM assays and competitive BM trans-
plant experiments. The results showed that, compared to
the control group, the number of CFU-GM in the TBI
group decreased significantly, and ATX treatment in-
creased the CFU-GM number in 4 Gy irradiated mice
(Fig. 4b). In the competitive BM transplant experiments,
lethally irradiated (CD45.1+) recipient mice were injected
with 1 × 106 donor (CD45.2+) BM cells from the mice in
the control group, control + ATX group, 4 Gy group, and
4 Gy + ATX group. At 2 month post-transplantation, we
measured donor-derived cells (CD45.2+) in the peripheral
blood of recipient mice by FACS. Chimerism of donor
cells from 4 Gy irradiated mice was significantly lower
than that of non-irradiated mice, while the 4 Gy + ATX
treatment transplanted group displayed a corresponding
increase in donor cell chimerism (Fig. 4c). These results
suggested that ATX promotes the recovery of HSC regen-
eration potential in 4 Gy irradiated mice.
ATX scavenges TBI-induced ROS in BM c-kit-positive cells
Exposure to irradiation can increase ROS generation which
may cause BM suppression [21]. ATX is increasingly used
in the nutritional and healthcare industry owing to its su-
perior anti-oxidant properties [22]. Therefore, to determine
whether ATX can attenuate TBI-induced BM suppression
by eliminating ROS, we measured the ROS production in
BM c-kit-positive cells 12 days after TBI by flow cytometry.
As shown in Fig. 5, the generation of ROS in c-kit-positive
cells, which was analyzed by DCFDA, DHE, and MitoSOX
staining, was significantly elevated after TBI compared to
Fig. 5 Astaxanthin (ATX) treatment inhibits total body irradiation (TBI)-induced reactive oxygen species (ROS) generation in BM c-kit-positive cells.
a The levels of ROS detected by the DCFDA MFI and the representative analysis of ROS levels by flow cytometry. b The levels of ROS detected by
the DHE MFI and the representative analysis of DHE levels by flow cytometry. c The levels of ROS in mitochondria detected by the MitoSOX MFI
and the representative analysis of MitoSOX levels by flow cytometry. The data are presented as the mean ± SEM (N = 5). aP < 0.05 vs control;
bP < 0.05 vs TBI
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non-irradiated mice. ATX treatment markedly attenuated
the elevation of ROS production detected by DCFDA and
MitoSOX, but not DHE, suggesting that ATX can effect-
ively scavenge TBI-induced ROS production, especially
those from mitochondria, while the scavenging effect of
ATX on superoxide anion free radicals was not as strong.
These results indicated that ATX acts as an inhibitor (anti-
oxidant) of TBI-mediated ROS generation.
Fig. 6 Astaxanthin (ATX) scavenges total body irradiation (TBI)-induced excessive ROS by upregulating NRF2 and its downstream anti-oxidant proteins.
a The NRF2 protein level in c-kit-positive cells was determined using the immunofluorescence method. b Expression of NRF2 protein was analyzed by
Western blotting. The enzyme activities of c SOD2, d CAT, and e GPX1 were analyzed by respective assay kit. The levels of intracellular f HO-1 and g
NQO1 expression was analyzed by flow cytometry. The data are presented as the mean ± SEM (N = 3 in b–e and N = 5 in f, g). aP < 0.05 vs
control; bP < 0.05 vs TBI. MFI mean fluorescence intensity
Xue et al. Stem Cell Research & Therapy  (2017) 8:7 Page 8 of 14
ATX upregulates expression of NRF2 and target anti-oxidant
proteins
Nrf2 is the central regulator of endogenous anti-oxidant
defense, the activation of which plays an important role in
regulating cellular redox homeostasis [10]. Western blot-
ting analysis and immunofluorescence assays showed that
TBI significantly upregulated NRF2 protein expression
and promoted nuclear translocation; these alterations
were enhanced by ATX (Fig. 6a and b). Furthermore, ATX
also increased the expression of NRF2-targeted proteins
HO-1 and NQO1 (Fig. 6f and g). It has been shown that
ATX attenuated intracellular ROS production in various
pathological conditions by restoring the anti-oxidant en-
zyme activities of SOD2, CAT, and GPX1 [23]. We found
that a decreased enzyme activity for SOD2, CAT, and
GPX1 was observed in irradiated c-kit-positive cells,
which were also enhanced by ATX (Figs. 6c–e). These
findings indicated that ATX suppresses ROS generation
by activating NRF2 and upregulating expression of related
anti-oxidant enzymes and proteins.
ATX decreases ROS levels in Nrf2−/− c-kit-positive cells
with TBI
To confirm the important role of Nrf2 in ATX-mediated
ROS scavenging, further experiments were conducted
to explore whether ATX decreased ROS levels in c-kit-
positive cells of irradiated Nrf2−/− mice. As shown in
Fig. 7, ATX indeed decreased the ROS levels in c-kit-
positive cells of irradiated Nrf2−/− mice as evidenced by
DCFDA and MitoSOX, but not DHE. These results
suggested that ATX mediated ROS scavenging in irradi-
ated c-kit-positive cells, partly by activation of the
Nrf2-dependent pathway.
ATX inhibits TBI-induced DNA DSBs and apoptosis in c-
kit-positive cells
TBI may induce DNA DSBs that lead to duplication and
transcriptional errors, cell apoptosis, or dysfunctional
cell growth, which finally results in hematopoietic dis-
eases [24]. We next performed flow cytometric analysis
of Annexin/PI staining and γH2AX staining to assess
Fig. 7 Astaxanthin (ATX) alleviates total body irradiation (TBI)-induced Nrf2−/− reactive oxygen species (ROS) generation in c-kit-positive cells. a The
levels of ROS detected by the DCF MFI and the representative analysis of ROS levels by flow cytometry. b The levels of ROS detected by the DHE
MFI and the representative analysis of DHE levels by flow cytometry. c The levels of ROS in mitochondria detected by the MitoSOX MFI and the
representative analysis of MitoSOX levels by flow cytometry. The data are presented as the mean ± SEM (N = 5). aP < 0.05 vs control; bP < 0.05 vs TBI
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the effects of ATX on c-kit-positive cell survival and DNA
damage. As shown in Fig. 8a, γH2AX staining in irradiated
c-kit-positive cells was significantly increased after TBI.
Conversely, treatment with ATX substantially reduced
TBI-induced DNA damage in c-kit-positive cells, as
shown by the reduced γH2AX level. Notably, the γH2AX
level of the irradiated c-kit-positive cells was almost at
normal levels after ATX treatment, indicating that ATX
treatment can ameliorate TBI-induced DSBs in c-kit-
positive cells. IR-induced cell death in HSCs predomin-
antly occurs by apoptosis but not by necrosis [5]; thus,
apoptosis was quantified (Fig. 8b). The percentage of
apoptotic cells increased significantly after irradiation
compared with non-irradiated cells, but ATX administra-
tion markedly reduced this trend. These findings showed
that ATX could prevent TBI-induced apoptosis of HSCs/
HPCs in vivo. Taken together, these findings suggested
that ATX significantly alleviated hematopoietic failure by
attenuating TBI-induced DNA damage and apoptosis in
c-kit-positive cells.
ATX alleviates TBI-induced BM suppression via modulation
of the apoptotic pathway
Cellular apoptosis is mediated by the balance of pro- and
anti-apoptotic proteins. Specifically, the apoptotic pathway
is regulated by early translocation of anti-apoptotic
(Bcl-xl) and pro-apoptotic (Bak and Bax) proteins to or
from the mitochondria [25]. Therefore, we assessed the
protein levels of BCL-XL, BAK, and BAX during apop-
tosis in c-kit-positive cells after TBI. The expression of
BCL-XL significantly decreased in the TBI group, while
the pro-apoptotic proteins showed the opposite trend.
However, ATX application significantly ameliorated the
increased expression of BAK and BAX and upregulated
the protein expression of BCL-XL compared with the
TBI groups (Fig. 9a). Next, we detected the cytochrome
C level both in cytosol and the mitochondria. Results
showed that TBI induced cytochrome C release from
the mitochondria to cytosol, while ATX significantly
blocked the efflux of cytochrome C from the mitochon-
dria (Fig. 9b). Compared to the control group, an upregu-
lated expression of cleaved CASPASE 3 was observed in
mice with TBI. ATX downregulated the expression of
cleaved CASPASE 3 in irradiated c-kit-positive cells.
These data suggested that ATX could reduce apoptosis in
c-kit-positive cells following TBI by regulating the apop-
totic pathway.
ATX improves the survival of lethally irradiated mice
In this study, to test whether ATX can increase the survival
of mice following TBI, mice were administered 50 mg/kg
ATX or DMSO from day −3 to day +7 following lethal
doses of TBI (7.2 Gy). The survival rate was monitored for
30 days after TBI. None of the control mice survived be-
yond 15 days after the lethal irradiation. In contrast, forty-
four percent of the ATX-treated mice remained alive
through day +30 (Fig. 10). These results suggested that
administration of ATX increased the survival of mice fol-
lowing a lethal dose of TBI.
Discussion
ATX is extensively used as food colorant and is approved
by the United States Food and Drug Administration (FDA)
Fig. 8 Astaxanthin (ATX) reduces total body irradiation (TBI)-induced
DNA DSBs and apoptosis in c-kit-positive cells. a Representative ana-
lysis of γH2AX expression in c-kit-positive cells by flow cytometry. b
Bar graph showing the percentage of apoptosis in c-kit-positive cells.
The data are presented as the mean ± SEM (N = 5). aP < 0.05 vs control;
bP < 0.05 vs TBI. MFI mean fluorescence intensity
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[26], and is a healthcare product to prevent several human
diseases owing to its natural source and superior anti-
oxidant activity [27, 28]. However, the therapeutic potential
of ATX as a radiation protectant or mitigator has not been
investigated. In the present study, we examined whether
ATX can attenuate TBI-induced hematopoietic system in-
jury. Consistent with previous studies, our results showed
that 4 Gy TBI can induce myelosuppression mainly due to
the generation of oxidative stress and the apoptosis of
HSCs and HPCs [29].
Under our experimental conditions, 50 mg/kg ATX ex-
hibited a greater protective activity than that from 25 mg/
kg or 100 mg/kg ATX. These data suggested that ATX at
low-doses was unable to efficiently protect mice against
TBI-induced injury, while ATX, one kind of carotenoid,
might cause a decrease in anti-oxidant capacity, and even
the promotion of the oxidation reaction [30]. There was
no significant difference in ROS level between TBI and
TBI + 100 mg/kg ATX (data not shown), indicating a simi-
lar anti-oxidant capacity in these two groups. Similar
Fig. 9 Astaxanthin (ATX) protects the hematopoietic system from total body irradiation (TBI) by regulating the apoptotic pathway. a The protein
expression of BAX, BAK, BCL-XL, and cleaved CASPASE 3 in c-kit-positive cells was analyzed by Western blotting. b Representative analysis of
cytochrome C (cyt C) release by flow cytometry. The data are presented as the mean ± SEM (N = 3 in a and N = 5 in b). aP < 0.05 vs control;
bP < 0.05 vs TBI. MFI mean fluorescence intensity
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observations with other protective agents, such as 3,3′-
diindolylmethane, ascorbic acid, and Xuebijing, were also
obtained in previous studies by us and other laboratories
[31–35]. ATX at 50 mg/kg ameliorated TBI-induced mye-
losuppression, increased the numbers of HPCs, and in-
creased self-renewal and differentiation ability in our
present study.
In our experiment, ATX rescued body weight and ROS
expression to a normal level 12 days after exposure to
TBI; however, the hematopoietic system was still under re-
covery and residual HSCs reconstituted the hematopoietic
system. Therefore, it is impossible for hematopoietic
makers and bone marrow cells to be rescued to normal
levels. Peripheral blood cell and bone marrow cell counts
can recover 2 months after exposure to a moderate dose
TBI while, because of persistent activation of ROS, TBI
causes bone marrow cell senescence and long-term
damage manifested as HSC pool exhaustion and severe
damage to the reconstructive ability of bone marrow.
Further studies are needed to explore the effect of ATX
on TBI-induced long-term hematopoietic injury.
It has been well established that TBI causes radiolysis of
intracellular water molecules, leading to increased produc-
tion of ROS [36]. As shown in our study, ATX markedly
mitigated ROS production detected by DCFDA and
MitoSOX, but not DHE, suggesting that ATX can scav-
enge ROS produced from mitochondria, but that it has no
scavenging effect on superoxide anion free radicals. No
change in SOD1 (which is found almost exclusively in
intracellular cytoplasmic spaces) enzyme activity was ob-
served in irradiated c-kit-positive cells treated with ATX
(data not shown), indicating a role of ATX in mitochon-
dria ROS scavenging. Prior studies showed that the Nrf2
anti-oxidant response element (ARE) pathway plays an
important role in the anti-oxidative effects of ATX [37].
Consistent with previous studies, our results showed that
ATX upregulated NRF2 expression in irradiated c-kit-
positive cells. Furthermore, the NRF2-targeted proteins
HO-1 and NQO1, and anti-oxidative enzymes SOD2,
CAT, and GPX1, were significantly upregulated in irradi-
ated c-kit-positive cells in the presence of ATX (Fig. 11).
To further explore the important role of Nrf2, Nrf2−/−
mice were employed in the absence and presence of ATX.
Results showed that ATX also decreased ROS level in c-
kit-positive cells of Nrf2−/− mice after TBI at 4 Gy. These
findings suggested that the radioprotective effects of ATX
are partly dependent on the regulation of Nrf2 and its tar-
geted proteins.
Previous studies have shown that overexpression of an
anti-apoptotic protein or downregulation of a pro-
apoptotic protein reduced IR-induced inhibition of
hematopoietic function [5]. Whether ATX attenuates TBI-
induced BM suppression by regulating the expression of
these apoptotic-related proteins has yet to be investigated.
Therefore, we used Western blot analysis to evaluate the
expression of apoptotic-related proteins in c-kit-positive
cells. Our results indicated that ATX-mediated inhibition
of hematopoietic cell apoptosis is dependent upon upreg-
ulation of the BCL-XL protein and dow-regulation of
BAX and BAK, members of the Bcl-2 family that are
involved in the apoptotic signaling pathway. ATX re-
duced apoptosis in c-kit-positive cells, revealing a new
anti-radiation property of this anti-oxidant. Song and
colleagues suggested that ATX inhibits apoptosis in
AECs-II via the ROS-dependent mitochondrial signaling
Fig. 10 Astaxanthin (ATX) administration increases survival. Mice
were treated with DMSO or ATX (50 mg/kg) by gavage for 3 days
before exposure to a lethal dose (7.2 Gy) of total body irradiation
(TBI) and then continuously for 7 days after TBI. Kaplan–Meier
analysis of mouse survival after exposure to the lethal dose of TBI
(N = 19 mice/group)
Fig. 11 A Summary on the radioprotective mechanism of astaxanthin
(ATX). ROS reactive oxygen species
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pathway, which is involved in inhibition of cytochrome
C and caspase-3 release, and activation of other cyto-
protective genes [25]. Our similar results showed that
ATX reduced cytochrome C release and the level of ac-
tivated CASPASE 3 expression following irradiation.
Therefore, ATX attenuates BM failure by inhibiting
hematopoietic cell apoptosis via regulating the intrinsic
apoptotic pathway (Fig. 11).
In addition, IR is extensively used to treat lung cancer
and malignant pelvic cancers, but the toxicity to the
surrounding healthy tissues limits the application of radio-
therapy. Radiation-induced lung fibrosis is one of the most
serious effects of lung cancer radiotherapy on normal tis-
sue, and gastrointestinal radiation toxicity is found in the
majority of patients treated for pelvic cancers [28, 38, 39].
Because ATX has been reported to ameliorate bleomycin-
induced pulmonary fibrosis in vitro and in vivo [28], it will
be interesting to determine whether ATX can also
ameliorate pulmonary fibrosis caused by IR. Further-
more, the dose of radiation that leads to the gastro-
intestinal syndrome was higher than that required for
inducing the hematopoietic syndrome [40, 41]; in the
future, we will explore the effect of ATX on gastro-
intestinal radiation toxicity in abdominal irradiation
models. ATX may thus have multiple therapeutic uses
for patients undergoing tumor radiotherapy.
Conclusions
Our results demonstrate that TBI induces apoptosis in
c-kit-positive cells and generates ROS, which lead to
hematopoietic cell depletion and destruction of the BM
reconstitution potential. Owing to its superior anti-oxidant
properties, ATX significantly ameliorates TBI-induced BM
suppression by inhibiting apoptosis of hematopoietic cells
and scavenging intracellular ROS. These findings suggest a
new strategy for protecting the hematopoietic system
against IR.
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